Our findings revealed that Egyptian BC patients may have more adverse molecular tumor characteristics, where the luminal-like BC subtype (72.8%) is the most current frequent subtype, followed by HER-2/neu overexpression (22.8%), and finally, TNBC (4.4%) is the least common. This evidence concerns the gene ERBB2 and neoplasm.